Toward Clinical Implementation of a Volumetric Absorptive Microsampling–Based Method for Dasatinib and Imatinib Therapeutic Drug Monitoring

Through a clinical validation study, the authors demonstrated that VAMS is a viable alternative for imatinib monitoring in patients with chronic myeloid leukemia. For dasatinib, VAMS-based analysis may still allow for longitudinal follow-up (ie, provide insight into fluctuations in patients). As a next step, capillary microsampling can be integrated into the home sampling context.